Last reviewed · How we verify

NCT03984890

Vitamin D3 For CGD Patients With BCGosis/Itis

Completed Phase 2, PHASE3 Last updated 9 July 2024
What this trial tests

Phase 2, PHASE3 trial testing Vitamin D3 in Vitamin D3 in 50 participants. Completed in 31 December 2023.

Timeline
1 August 2019
Primary endpoint
31 December 2021
31 December 2023

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment50
Start date1 August 2019
Primary completion31 December 2021
Estimated completion31 December 2023
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Under 18, any sex, with Vitamin D3 or Chronic-granulomatous Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

When children with chronic granulomatous disease (CGD) got BCG infection the treatment would be a tough task. The goal of the proposed research is to observe weather vitamin D supplementation can help the CGD children get through this challenge.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vitamin D3

Trials testing the same drug.

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03984890.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing